| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 29 Jan 2026 | 16 Jan 2026 |
| Eiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/01/2026 inter alia to consider and approve Unaudited standalone and consolidated FInancial results for quarter ended 31st December 2025 | ||
| Board Meeting | 11 Dec 2025 | 8 Dec 2025 |
| Eiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/12/2025 inter alia to consider and approve As per attachment Outcome of the Board Meeting (As per BSE Announcement dated on: 11.12.2025) | ||
| Board Meeting | 31 Oct 2025 | 17 Oct 2025 |
| Eiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/10/2025 ,inter alia, to consider and approve Unaudited Financial Results (Standalone and Consolidated basis) for quarter and half year ended on 30th September, 2025 Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), and amendments thereto, this is to inform that the Meeting of the Board of Directors of the Company held today i.e., on Friday, 31st October, 2025, Board, inter-alia, considered and approved Un-Audited Financial Results (Standalone & Consolidated basis) for the Quarter and Half Year ended 30th September, 2025 along with Limited Review Report The Meeting was commenced at 04: 45 PM and concluded at 5:30 PM. (As Per BSE Announcement Dated on:31.10.2025) | ||
| Board Meeting | 29 Jul 2025 | 24 Jul 2025 |
| Eiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2025 inter alia to consider and approve The meeting of Board of Directors of the Company is scheduled to be held on Tuesday 29th July 2025 inter-alia to consider and approve the following: 1. The Unaudited Financial Results (Standalone & Consolidation basis) of the Company for the quarter ending on 30th June 2025 in accordance with Regulation 33 of the SEBI Listing Regulation. 2. Any other matter with the permission of the chair. As per attachment (As Per BSE Announcement Dated on: 29.07.2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
